Analysts think PLUR stock price could decrease by -30%

Pluri, Inc. is a clinical stage company focused on developing cell therapies like PLX-PAD and PLX R18, primarily for conditions such as critical limb ischemia, femoral neck fracture recovery, and acute radiation syndrome. Their technology involves expanding placental-derived stromal cells in a synthetic 3D scaffold, with products administered via standard injection and targeting various medical fields.